<DOC>
	<DOCNO>NCT02396511</DOCNO>
	<brief_summary>The purpose study determine whether TRC105 combination Bevacizumab effective treatment one patient metastatic refractory choriocarcinoma .</brief_summary>
	<brief_title>Single Patient Treatment Protocol TRC105 Combined With Standard-dose Bevacizumab Single Patient With Metastatic And Refractory Choriocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Willingness ability consent self participate study 2 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure 3 . Measurable disease RECIST 1.1 elevate serum βhCG 4 . Histologically proven choriocarcinoma progress despite described line chemotherapy condition 1 . Prior treatment TRC105 2 . Serious doselimiting toxicity relate prior bevacizumab 3 . Current treatment another therapeutic clinical trial 4 . Uncontrolled chronic hypertension define systolic &gt; 140 diastolic &gt; 90 despite optimal therapy ( initiation adjustment BP medication prior study entry allow provided average 3 BP reading visit prior enrollment &lt; 140/90 mm Hg ) 5 . Symptomatic pericardial pleural effusion 6 . Uncontrolled peritoneal effusion require paracentesis frequently every 2 week 7 . Active bleed pathologic condition carry high risk bleeding ( i.e . hereditary hemorrhagic telangiectasia ) 8 . Thrombolytic anticoagulant use ( except maintain i.v . catheter ) within 10 day prior first day study therapy 9 . Cardiac dysrhythmias NCI CTCAE grade ≥ 2 within last 28 day 10 . Known active viral nonviral hepatitis 11 . Open wound unhealed fracture within 28 day start study treatment 12 . History peptic ulcer disease erosive gastritis within past 6 month , unless treat condition complete resolution document esophagogastroduodenoscopy ( EGD ) within 28 day start study treatment 13 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness 14 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation may interfere interpretation study result , judgment Investigator , would make patient inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>